Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
Shares of Dianthus Therapeutics surged Monday after the company's autoimmune disease treatment succeeded in a midstage study.
| Ticker |
ARGX
|
| CIK | 0001697862 |
| SIC | 2836 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Biological Products, Except Diagnostic Substances |
| Address | INDUSTRIEPARK ZWIJNAARDE 7, BUILDING C B-9052, ZWIJNAARDE, C9, B-9052 |
| Website | argenx.com |
| Phone | 32 (9) 310 34 00 |
| CEO | Tim v. Hauwermeiren |
| Employees | 650 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged AgainShares of Dianthus Therapeutics surged Monday after the company's autoimmune disease treatment succeeded in a midstage study. A Closer Look at argenx (ENXTBR:ARGX) Valuation Following Positive VYVGART Study Results and Label Expansion Plansargenx (ENXTBR:ARGX) just made waves with its recent announcement that the ADAPT SERON study for VYVGART delivered statistically significant and clinically meaningful results in treating AChR-Ab seronegative generalized myasthenia gravis patients. By meeting the primary endpoint, this topline data means argenx can now move forward with a planned submission to expand the VYVGART label, covering additional patient subtypes. For investors, this development stands out as a potential turning point... Immunovant's New Data Shows Batoclimab's Potential to Replace Current Graves' Disease Options, Oppenheimer SaysImmunovant's (IMVT) new batoclimab data show the treatment's potential to offer an alternative to cu European Equities Traded in the US as American Depositary Receipts Rise in Thursday TradingEuropean equities traded in the US as American depositary receipts were higher late Thursday morning Hemab Therapeutics Expands Leadership with Appointment of Anant Murthy, PhD, as Chief Operating OfficerHemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the appointment of Anant Murthy, PhD, as Chief Operating Officer. In this new role, Murthy will lead the company's global efforts in market access, launch, and commercialization, bringing Hemab's promising pipeline of treatments for Glanzmann thrombasthenia (GT), Von Willebrand disease (VWD), and other neglected blood cl |